Carbaglu approved for N-acetylglutamate synthase (NAGS) deficiency - MPR
Links shared publicly online about this topic.
- 1,303total visits
Carbaglu approved for N-acetylglutamate synthase (NAGS) deficiency - MPR
empr.com —
The FDA has approved Carbaglu (carglumic acid tablets, from Orphan Europe) for the treatment of the genetic disorder N-acetylglutamate synthase (NAGS) deficiency, which causes hyperammonemia.
View full resource at empr.com
Tags: Genetic, Disease and Condition, FDA, News
Most Recently Shared on March 19, 2010 at 3:43 pm By:
MPR News: Carbaglu approved for N-acetylglutamate synthase (NAGS) deficiency: The FDA has approved Carbaglu (cargl... http://bit.ly/bkk4fM
Advertisement
